Peripheral neuropathy encompasses a vast and diverse set of conditions — diabetic, alcoholic, vitamin-deficient, chemotherapy-induced, immune-mediated (CIDP, Guillain-Barré, paraproteinemic, vasculitic), hereditary (Charcot-Marie-Tooth), infectious (HIV, leprosy, Lyme), and toxic. Beyond symptomatic neuropathic pain management (covered separately), specific etiologies require disease-modifying approaches. This page focuses on the disease-specific pharmacotherapy of major neuropathy categories.

Diabetic Peripheral Neuropathy

Disease Modification

  • Glycemic control: most important; type 1 DM responds best to early control; type 2 effect smaller.
  • BP control, lipid management.
  • Alpha-lipoic acid: modest benefit in some studies (controversial).
  • Benfotiamine: limited evidence.

Symptomatic

  • Duloxetine, pregabalin, gabapentin, amitriptyline (see neuropathic pain page).
  • Topical lidocaine.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

First-Line Treatments

  • IVIG: 2 g/kg over 2-5 days induction; maintenance 0.4-1 g/kg every 3-6 weeks.
  • Corticosteroids: prednisone or methylprednisolone pulses.
  • Plasmapheresis: alternative when IVIG fails.

Maintenance

  • Subcutaneous IG (Hizentra, Hyqvia): home maintenance; weekly to monthly.
  • Repeat IVIG cycles.
  • Corticosteroid maintenance with steroid-sparing.
  • Mycophenolate, azathioprine as steroid-sparing.
  • Rituximab: refractory cases.

CIDP Variants

  • Multifocal motor neuropathy (MMN): IVIG mainstay; steroids may worsen.
  • POEMS syndrome: treat underlying plasma cell disorder.

Guillain-Barré Syndrome (GBS)

  • IVIG: 0.4 g/kg/day × 5 days; first-line.
  • Plasmapheresis: alternative; equivalent efficacy.
  • Corticosteroids: NOT effective; DO NOT use.
  • Respiratory monitoring (FVC, NIF).
  • Supportive care: cardiac monitoring (autonomic instability), DVT prophylaxis, pain management.

Vitamin Deficiency Neuropathies

Vitamin B12 Deficiency

  • Cobalamin replacement: oral (1000-2000 μg daily) or IM (1000 μg).
  • Check methylmalonic acid + homocysteine if borderline B12.
  • Address cause: pernicious anemia, malabsorption, dietary, metformin.

Vitamin E Deficiency

  • Vitamin E replacement.
  • Often in malabsorption syndromes (cystic fibrosis, abetalipoproteinemia).

Vitamin B1 (Thiamine) Deficiency

  • Beriberi; Wernicke encephalopathy; alcoholic neuropathy.
  • IV thiamine 500 mg TID × 3 days for Wernicke (BEFORE glucose); then 100 mg daily.
  • Long-term: oral thiamine.

Vitamin B6 (Pyridoxine)

  • Deficiency: rare; isoniazid causes deficiency neuropathy.
  • Excess: paradoxical sensory neuropathy from high-dose B6.

Vitamin B3 (Niacin)

  • Pellagra: niacin replacement.

Copper Deficiency

  • Bariatric surgery, zinc overuse.
  • Copper replacement.

Vasculitic Neuropathy

  • Treatment: aggressive immunosuppression.
  • Induction: steroids + cyclophosphamide or rituximab.
  • Maintenance: azathioprine, methotrexate, mycophenolate, rituximab.
  • Address underlying systemic vasculitis (GPA, EGPA, polyarteritis nodosa).
  • Nonsystemic vasculitic neuropathy: similar approach.

Paraproteinemic Neuropathies

IgM-Related (Anti-MAG, etc.)

  • Often slow chronic course.
  • Rituximab: emerging evidence.
  • IVIG: limited benefit.
  • Steroids: minimal benefit usually.

POEMS Syndrome

  • Treat underlying plasma cell disorder (lenalidomide, dexamethasone, melphalan, autologous SCT).

Amyloidosis

  • AL amyloid: treat underlying plasma cell disorder.
  • ATTR amyloid:
    • Tafamidis (Vyndaqel): stabilizes transthyretin.
    • Inotersen (Tegsedi): ASO; reduces TTR production.
    • Patisiran (Onpattro): siRNA; reduces TTR production.
    • Vutrisiran (Amvuttra): siRNA; less frequent dosing than patisiran.

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

  • Most preventable approach: dose modification of chemotherapy.
  • Duloxetine: emerging evidence for established CIPN.
  • Topical menthol some benefit.
  • Acupuncture: emerging evidence.
  • Cryotherapy during oxaliplatin: prevention.

HIV-Related Peripheral Neuropathy

  • ART optimization (avoid neuropathy-inducing agents when possible).
  • Gabapentinoids for pain.
  • Topical lidocaine, capsaicin.

Charcot-Marie-Tooth (CMT)

Disease-Specific

  • No disease-modifying therapy currently.
  • Investigational: gene therapy for specific mutations.
  • Supportive: braces, PT, OT.

Symptomatic

  • Neuropathic pain management.
  • Orthotics.
  • Surgery for severe foot deformity.

Hereditary Neuropathies — Specific Treatments

Familial Amyloid Polyneuropathy (ATTR)

  • Tafamidis, inotersen, patisiran, vutrisiran (as above).

Fabry Disease

  • Enzyme replacement: agalsidase α or β.
  • Migalastat: small-molecule chaperone for amenable mutations.
  • Pegunigalsidase alfa: emerging.

Refsum Disease

  • Dietary phytanic acid restriction.
  • Plasmapheresis for acute decompensation.

Krabbe Disease, Metachromatic Leukodystrophy, GLD

  • Hematopoietic stem cell transplant (limited effect on PNS).
  • Gene therapy emerging.

Toxic Neuropathies

  • Lead, arsenic, mercury, thallium: chelation (succimer, EDTA, dimercaprol).
  • Alcohol: abstinence; nutritional repletion.
  • Chemotherapy: dose modification.
  • Medications: discontinue offending drug.

Infectious Neuropathies

Leprosy

  • Multi-drug therapy: rifampin + dapsone + clofazimine for multibacillary; rifampin + dapsone for paucibacillary.
  • Treat reactions (steroids for type 1 reversal reaction; thalidomide for type 2 ENL).

Lyme Neuroborreliosis

  • IV ceftriaxone 2 g daily × 14-28 days.
  • Or oral doxycycline 200 mg daily × 28 days (in many cases).

Diphtheria

  • Antitoxin + antibiotics.

HIV

  • Antiretroviral therapy.

Critical Illness Neuropathy/Myopathy

  • Prevent: minimize neuromuscular blockade, glucose control, early mobilization.
  • Recovery often takes months.
  • No specific pharmacotherapy.

Specific Drug-Induced Neuropathies

  • Vincristine, cisplatin, paclitaxel, oxaliplatin: chemotherapy.
  • Statins: rare myopathy/neuropathy.
  • Amiodarone: rare neuropathy.
  • Metronidazole: chronic high-dose.
  • Isoniazid: B6 deficiency-related.
  • Linezolid: rare neuropathy.
  • Pyridoxine high-dose: sensory.
  • Discontinue when possible.

Idiopathic Neuropathy

  • Diagnostic workup important first.
  • Symptomatic pain management.
  • Some respond to immunotherapy if subtle features suggest immune cause.

🔍 Did You Know?

The development of RNA-based medicines for hereditary transthyretin (ATTR) amyloidosis — patisiran (siRNA), vutrisiran (siRNA), inotersen (ASO), and tafamidis (small-molecule TTR stabilizer) — represents one of the most successful applications of gene-targeted therapy in modern medicine. ATTR amyloidosis causes progressive sensory and autonomic neuropathy, cardiomyopathy, and gastrointestinal symptoms, historically with poor prognosis. The molecular approach is elegant: silencing TTR mRNA (siRNAs and ASOs) or stabilizing the TTR tetramer (tafamidis) prevents formation of toxic amyloid fibrils. Clinical impact has been transformative: patisiran reduced TTR levels by 80%+, significantly improved neuropathy outcomes in APOLLO trial, with vutrisiran offering similar benefits with quarterly dosing (vs every 3 weeks for patisiran). For the cardiomyopathy form, tafamidis significantly reduced mortality in ATTR-CM. The lesson generalizes: identifying the specific protein causing disease can lead to targeted therapy that addresses the root cause, and RNA-based medicines (ASOs, siRNAs) are emerging as a powerful class of CNS- and PNS-active therapeutics. The same principle is being applied to other amyloidoses, prion diseases, ALS subtypes (tofersen), Huntington disease, and many others. For practicing neurologists treating neuropathy, the take-home: genetic testing for hereditary causes opens treatment doors, and the ATTR success story should prompt screening in patients with appropriate phenotypes (sensorimotor + autonomic + cardiomyopathy + family history). Cost remains high but coverage is improving as evidence accumulates.

Pitfalls and Pearls

  • Diabetic neuropathy: glycemic control; symptomatic management.
  • CIDP: IVIG first-line; SCIG for maintenance; steroids; rituximab refractory.
  • GBS: IVIG or plasmapheresis; steroids NOT effective.
  • B12 deficiency: oral or IM replacement.
  • Wernicke: IV thiamine BEFORE glucose.
  • Pyridoxine excess: paradoxical sensory neuropathy.
  • Vasculitic neuropathy: steroids + cyclophosphamide or rituximab.
  • ATTR amyloidosis: tafamidis, patisiran, vutrisiran, inotersen.
  • Multifocal motor neuropathy: IVIG mainstay; AVOID steroids.
  • POEMS syndrome: treat plasma cell disorder.
  • Fabry disease: enzyme replacement; migalastat for amenable mutations.
  • CIPN: dose modification key; duloxetine for established.
  • Lyme neuroborreliosis: ceftriaxone IV or doxycycline.
  • Leprosy: multi-drug therapy.
  • Critical illness neuropathy: prevention; supportive recovery.
  • Toxic neuropathies: identify and remove cause.
  • Idiopathic neuropathy: thorough workup before labeling as such.

References

  1. Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis (APOLLO). N Engl J Med. 2018;379(1):11-21.
  2. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. Brain. 1996;119(Pt 4):1055-1066.
  3. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005;366(9497):1653-1666.
  4. Cocito D, Paolasso I, Antonini G, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2010;17(2):289-294.
  5. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-ACT). N Engl J Med. 2018;379(11):1007-1016.